Beatriz Rizkallah Alves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Beatriz Rizkallah Alves has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ariane Paz Y Miño
Unidad de Investigaciones en Biomedicina. Zurita & Zurita Laboratorios, Quito, Ecuador; Mass General Brigham Salem Hospital, Salem, MA, USA
2 shared publications - Jeannete Zurita
Pontificia Universidad Católica del Ecuador, Facultad de Medicina, Quito, Ecuador; Unidad de Investigaciones en Biomedicina, Zurita & Zurita Laboratorios, Quito, Ecuador
2 shared publications - Camilo Zurita-Salinas
Biomedical Research Unit,Zurita & Zurita Laboratories,Quito,Ecuador, Ecuador
1 shared publication - Daniel B. Rubin
Ctr. for Neurotechnology and Neurorecovery, Dept. of Neurology, Massachusetts General Hospital, Boston, MA, USA
1 shared publication Ecuadorian Bacteremia
Ecuadorian Bacteremia Working Group , Quito, Pichincha , Ecuador
1 shared publicationGabriela Sevillano
Unidad de Investigaciones en Biomedicina. Zurita & Zurita Laboratorios, Quito, Ecuador
1 shared publication
Latest Publications
- Open Access
- 16 July 2024
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 38, 332-338
Pseudomonas aeruginosa epidemic high-risk clones and their association with multidrug-resistant
- 16 July 2024
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 38, 332-338
Open AccessPseudomonas aeruginosa epidemic high-risk clones and their association with multidrug-resistant
- 28 November 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (22) , E2338-E2339
Teaching NeuroImage: CHANTER Syndrome
- 28 November 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (22) , E2338-E2339
Teaching NeuroImage: CHANTER Syndrome
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
226. Low incidence of Pseudomonas species in Gram negative blood stream infections in nine hospitals across Ecuador: an unexpected find
Over the last years, several studies on bloodstream infections (BSI) have ranked P. aeruginosa in the top 5 list of Gram-negative causal agents. However, there is very limited data regarding the incidence of Pseudomonas bacteremia in Latin America. The aim of this study was to establish the incidence of bacteremia caused by Pseudomonas species During the period from November 2021 to May 2022 in 9 hospitals in Ecuador, blood culture samples were taken according to the clinical requirements of each patient. The bacteria identification was carried out using automated system (Vitek2 and Phoenix1000) and was confirmed by proteomic (MALDITOF) and molecular sequencing. Antimicrobial susceptibility was performed according to CLSI 2021. This study provided relevant information on BSI caused by Pseudomonas in Ecuador.There are only few population-based studies evaluating bacteremia epidemiology in Latin America. SENTRY in 1997 estimated that P. aeruginosa contributed to 10.6% of gram-negative nosocomial and community-acquired bloodstream infections. Lower incidence levels, as seen in this study (0.043%), could help better understand population trends and help guide treatment. Jeannete Zurita, n/a, Pfizer: Grant/Research Support
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access226. Low incidence of Pseudomonas species in Gram negative blood stream infections in nine hospitals across Ecuador: an unexpected find
Over the last years, several studies on bloodstream infections (BSI) have ranked P. aeruginosa in the top 5 list of Gram-negative causal agents. However, there is very limited data regarding the incidence of Pseudomonas bacteremia in Latin America. The aim of this study was to establish the incidence of bacteremia caused by Pseudomonas species During the period from November 2021 to May 2022 in 9 hospitals in Ecuador, blood culture samples were taken according to the clinical requirements of each patient. The bacteria identification was carried out using automated system (Vitek2 and Phoenix1000) and was confirmed by proteomic (MALDITOF) and molecular sequencing. Antimicrobial susceptibility was performed according to CLSI 2021. This study provided relevant information on BSI caused by Pseudomonas in Ecuador.There are only few population-based studies evaluating bacteremia epidemiology in Latin America. SENTRY in 1997 estimated that P. aeruginosa contributed to 10.6% of gram-negative nosocomial and community-acquired bloodstream infections. Lower incidence levels, as seen in this study (0.043%), could help better understand population trends and help guide treatment. Jeannete Zurita, n/a, Pfizer: Grant/Research Support